In QuotedData’s morning briefing 4 November 2024:
- Partners Group Private Equity (PEY/PEYS) saw its NAV increase by 0.5% during September to €14.24 per share, with total net assets at €984.62m. PEY says that positive value creation (0.9%) was partially offset by adverse currency movements (-0.3%). KinderCare, PEY’s fifth largest portfolio company, was the largest contributor to the NAV increase following its IPO pricing. PGPE Ltd invested €6.7m and received distributions of €6.3m during September, of which €5.5m was in FairJourney Biologics, a European antibody discovery Contract Research Organization (CRO) based in Porto, Portugal. Founded in 2012, FairJourney provides services for the discovery, engineering, production, and characterization of antibodies. PEY says that FairJourney is set to benefit from structural market tailwinds, including increased R&D spend, outsourcing trends, and a favorable regulatory landscape. Distributions of €6.0m came from the sale of a portion of PEY’s stake in Galderma, a pure-play dermatology category leader. The shares were sold to L’Oréal, via an off-market block trade that saw the French beauty and cosmetics group invest for a 10% stake in Galderma. The two companies have also agreed on a scientific partnership to develop advanced, future-proof technologies with direct applications in the field of dermatology.
- Sirius Real Estate (SRE) announced that Fitch Ratings has reaffirmed its long-term issuer default rating and senior unsecured rating at BBB, with a ‘Stable Outlook’.
We also have:
JPMorgan Global Emerging Markets Income performance aligns closely with benchmark